XLO Xilio Therapeutics, Inc.
Price Chart
Executive Summary
Xilio Therapeutics reported Q1 2026 results with collaboration revenue of $12.6M (up from $2.9M a year ago) and a net loss of $9.5M ($0.58 per share), beating the consensus EPS estimate of -$0.66. The company highlighted a $6.0M AbbVie milestone achieved in Q2 and extended its cash runway into early 2028, while advancing pipeline programs toward IND filings in mid-2026.
Actionable Insight
The significant EPS beat and extended cash runway into 2028 reduce near-term dilution risk. Key catalysts to watch: XTX501 IND submission (mid-2026), Phase 1 initiation (H2 2026), and potential AbbVie milestones up to $31M through H1 2027. The warrant exercise potential ($36.2M) adds upside optionality. Monitor for any delays in IND filings or clinical starts.
Key Facts
- Q1 2026 collaboration revenue $12.6M vs $2.9M YoY
- Net loss $9.5M ($0.58/share) vs consensus -$0.66 — 222.7% EPS beat
- Cash and equivalents $150.3M as of March 31, 2026, up from $137.5M at year-end 2025
- Achieved $6.0M development milestone under AbbVie collaboration in Q2 2026
- Cash runway extended into early 2028
- On track for XTX501 IND submission mid-2026 and Phase 1 initiation H2 2026
- Preclinical data for XTX601 (CLDN18.2 TCE) presented at AACR April 2026
- Potential for up to $31.0M in additional near-term milestones from AbbVie through H1 2027
- Up to $36.2M in additional gross proceeds if all Series C warrants exercised in H2 2026
Financial Impact
EPS beat of 222.7% vs consensus; collaboration revenue increased 331% YoY; cash position increased $12.8M from year-end 2025
Risk Factors
- Preclinical/clinical failure risk — XTX501 and TCE programs are early-stage
- Dilution risk from Series C warrant exercises ($36.2M potential gross proceeds)
- Dependence on AbbVie and Gilead collaborations for milestone revenue
- Net loss of $9.5M in Q1 2026 with R&D spending increasing 140% YoY
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292720 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
14d ago
|
EFFECT
| $8.25 $7.70 | ▲ +6.67% | ▲ +3.92% | $8.31 (−0.73%) |
|
May 27, 2026
18d ago
|
S-3/A
| $8.52 $8.15 | ▼ −4.40% | ▼ −4.35% | $8.31 (−2.46%) |
|
May 12, 2026
4w ago
|
8-K
| $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.31 (+7.50%) |
|
May 12, 2026
4w ago
|
Press Release
| $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.31 (+7.50%) |
|
Apr 17, 2026
8w ago
|
Press Release
| $8.45 $8.18 | ▼ −3.20% | ▼ −4.11% | $8.31 (−1.66%) |
|
Apr 16, 2026
8w ago
|
3
| $8.57 $8.31 | ▼ −3.03% | ▼ −3.59% | $8.31 (−3.03%) |
|
Apr 16, 2026
8w ago
|
8-K
| $8.35 $8.47 | ▲ +1.44% | ▲ +0.45% | $8.31 (−0.48%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $7.86 $8.24 | ▲ +4.77% | ▲ +8.34% | $8.31 (+5.73%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $7.60 $8.53 | ▲ +12.24% | ▲ +12.95% | $8.31 (+9.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access